Ace Vision Group Names Ken Araki to Its Board of Directors
Ace Vision Group, Inc., an emerging medical device company at the forefront of pioneering rejuvenation therapy for the aging eye, today announced that it has named Ken Araki to its board of directors. Mr. Araki brings executive management experience and strategic leadership skills to support and drive commercial planning for the VisioLite® laser. The laser restores the eye’s natural dynamic range of focus through Laser Scleral Microporation (LSM), allowing patients to see clearly at all distances with the eye’s natural functionality. The VisioLite® Ophthalmic Laser System & LSM are not yet FDA approved or available in the United States. It is currently in clinical trials only in select areas outside of the United States.
Explore More Articles
Laser scleral microporation may solve biomechanical problem of presbyopia
CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Alex Lopez of Ace Vision Group discusses laser scleral microporation for presbyopia. Lopez said the GenII device can potentially deliver improved near vision without compromising distance vision in patients with presbyopia. The company plans to do a study in the United States in 2026, potentially leading to commercial availability in …
read moreEmerging medical and surgical presbyopic treatments
Ophthalmologists have several options at their disposal for the treatment of presbyopia, according to Elizabeth Yeu, MD, a partner at Virginia Eye Consultants and an assistant professor at Eastern Virginia Medical School in Norfolk. Speaking recently at the virtual 2022 Toronto Cataract Course, Yeu noted that innovation is advancing in presbyopia correction. “We have spent …
read more